18 results on '"Neelakantan, Pratap"'
Search Results
2. Optimisation of CML therapy
3. PB1886: REAL WORLD EXPERIENCE OF VENETOCLAX-AZACYTIDINE COMBINATION IN FRAIL ELDERLY PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY
4. sj-docx-2-tah-10.1177_20406207221084487 – Supplemental material for A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study
5. sj-docx-3-tah-10.1177_20406207221084487 – Supplemental material for A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study
6. sj-docx-1-tah-10.1177_20406207221084487 – Supplemental material for A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study
7. sj-docx-4-tah-10.1177_20406207221084487 – Supplemental material for A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study
8. A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study
9. Low Incidence of COVID-19 Infection in Patients with Acute Myeloid Leukemia Undergoing Reduced Intensity/Venetoclax Based Treatment: Initial Results of the PACE Prospective Clinical Study from the UK Trials Acceleration Program
10. Nilotinib for treatment of chronic myeloid leukemia in light of the current evidence and guidelines
11. A Retrospective Real-World Study of the Current Treatment Pathways for Myelofibrosis in the UK (The REALISM UK Study)
12. Sequence of Second Generation Tyrosine Kinase Inhibitors (TKIs) in the Treatment of Patients with Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia - Real World Experience in the UK
13. Breast cancer metastasizing to the tongue
14. The transformative journey of chronic myeloid leukemia
15. Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies
16. Is Major Molecular Response a Safe Haven Against Blast Crisis in Cml Patients Treated with Imatinib?
17. Can the Combination of the Measurement of BCR-ABL1 Transcript Levels At 3 and 6 Months Improve the Prognostic Value of the 3 Month Measurement?
18. Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.